293 related articles for article (PubMed ID: 19473416)
1. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
Martinowitz U; Livnat T; Zivelin A; Kenet G
Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
[TBL] [Abstract][Full Text] [Related]
2. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
Bonnet PO; Yoon BS; Wong WY; Boswell K; Ewenstein BM
Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876
[TBL] [Abstract][Full Text] [Related]
3. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
Holme PA; Glomstein A; Grønhaug S; Tjønnfjord GE
Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
[TBL] [Abstract][Full Text] [Related]
4. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
5. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Livnat T; Martinowitz U; Zivelin A; Seligsohn U
Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
[TBL] [Abstract][Full Text] [Related]
6. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
[TBL] [Abstract][Full Text] [Related]
7. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
[TBL] [Abstract][Full Text] [Related]
8. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
Valentino LA
Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
[TBL] [Abstract][Full Text] [Related]
9. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.
Salaj P; Brabec P; Penka M; Pohlreichova V; Smejkal P; Cetkovsky P; Dusek L; Hedner U
Haemophilia; 2009 May; 15(3):752-9. PubMed ID: 19432926
[TBL] [Abstract][Full Text] [Related]
10. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
11. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre.
Smejkal P; Brabec P; Matyskova M; Bulikova A; Slechtova M; Kissova J; Chlupova G; Muzik J; Penka M
Haemophilia; 2009 May; 15(3):743-51. PubMed ID: 19432925
[TBL] [Abstract][Full Text] [Related]
12. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
13. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson K; Astermark J; Donfield S; Berntorp E
Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
[TBL] [Abstract][Full Text] [Related]
14. Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2010 Mar; 16(2):366-8; discussion 369-71. PubMed ID: 19811544
[No Abstract] [Full Text] [Related]
15. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
Livnat T; Martinowitz U; Zivelin A; Rima D; Kenet G
Thromb Haemost; 2011 Apr; 105(4):688-95. PubMed ID: 21225093
[TBL] [Abstract][Full Text] [Related]
16. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
17. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.
Putnam KG; Bohn RL; Ewenstein BM; Winkelmayer WC; Avorn J
Haemophilia; 2005 May; 11(3):261-9. PubMed ID: 15876272
[TBL] [Abstract][Full Text] [Related]
18. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.
Kraut EH; Aledort LM; Arkin S; Stine KC; Wong WY
Haemophilia; 2007 Sep; 13(5):508-17. PubMed ID: 17880437
[TBL] [Abstract][Full Text] [Related]
19. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
Valentino LA
Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
Knight C; Danø AM; Kennedy-Martin T
Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]